3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide has been researched along with risperidone in 16 studies
| Studies (3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide) | Trials (3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide) | Recent Studies (post-2010) (3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide) | Studies (risperidone) | Trials (risperidone) | Recent Studies (post-2010) (risperidone) |
|---|---|---|---|---|---|
| 330 | 40 | 33 | 6,924 | 1,505 | 2,477 |
| Protein | Taxonomy | 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide (IC50) | risperidone (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.015 | |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.0027 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.0097 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 5.2734 | |
| Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | 4.1901 | |
| D(2) dopamine receptor | Homo sapiens (human) | 0.0167 | |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.0991 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.026 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.0096 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.799 | |
| D(1A) dopamine receptor | Homo sapiens (human) | 0.479 | |
| Histamine H2 receptor | Homo sapiens (human) | 1.483 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.01 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.0016 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.0057 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.799 | |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.0027 | |
| 5-hydroxytryptamine receptor 2C | Mus musculus (house mouse) | 0.0015 | |
| Alpha-1A adrenergic receptor | Homo sapiens (human) | 0.0105 | |
| 5-hydroxytryptamine receptor 2A | Mus musculus (house mouse) | 0.0015 | |
| Histamine H1 receptor | Homo sapiens (human) | 0.4515 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.024 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.023 | |
| D(2) dopamine receptor | Mus musculus (house mouse) | 0.023 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.0154 | |
| 5-hydroxytryptamine receptor 2B | Mus musculus (house mouse) | 0.0015 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 0.6303 | |
| 5-hydroxytryptamine receptor 1A | Mus musculus (house mouse) | 0.43 | |
| Nuclear receptor subfamily 3 group C member 3 | Bos taurus (cattle) | 4.1901 | |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | 1.6 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (62.50) | 18.2507 |
| 2000's | 6 (37.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Busatto, GF; Costa, DC; Ell, PJ; Kerwin, RW; Pilowsky, LS; Verhoeff, NP | 2 |
| Asenbaum, S; Brücke, T; Gössler, R; Kasper, S; Küfferle, B; Podreka, I; Tauscher, J; Topitz-Schratzberger, A; Vesely, C | 1 |
| Breier, A; Hadd, K; Malhotra, AK; Pickar, D; Su, TP | 1 |
| Heinz, A; Knable, MB; Raedler, T; Weinberger, DR | 1 |
| Asenbaum, S; Barnas, C; Brücke, T; Hesselmann, B; Kasper, S; Küfferle, B; Podreka, I; Tauscher, J | 1 |
| Coppola, R; Gorey, JG; Heinz, A; Jones, DW; Knable, MB; Lee, KS; Weinberger, DR | 1 |
| Dähne, I; Dresel, S; Hahn, K; Mager, T; Scherer, J; Tatsch, K | 1 |
| Dresel, S; Hahn, K; Mager, T; Meisenzahl, E; Möller, HJ; Rossmüller, B; Tatsch, K | 1 |
| Booij, J; Gersons, BP; Lavalaye, J; Linszen, DH; Reneman, L; van Royen, EA | 1 |
| Booij, J; de Haan, L; Dingemans, PM; Lavalaye, J; Linszen, D | 1 |
| Gertz, HJ; Hohdorf, K; Künstler, U; Regenthal, R; Seese, A | 1 |
| Bressan, RA; Ell, PJ; Jones, HM; Pilowsky, LS | 1 |
| Dresel, S; Frodl, T; Hahn, K; Meisenzahl, EM; Möller, HJ; Preuss, UW; Rossmüller, B; Schmitt, GJ; Tatsch, K | 1 |
| Abi-Dargham, A; Cangiano, C; Frankle, WG; Gil, R; Gorman, JM; Hackett, E; Kochan, LD; Laruelle, M; Mawlawi, O; Slifstein, M; Zea-Ponce, Y; Zhu, Z | 1 |
| Alvarez, E; Carrió, I; Catafau, AM; Corripio, I; Martin, JC; Pérez, V; Schotte, A | 1 |
4 trial(s) available for 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide and risperidone
| Article | Year |
|---|---|
Dopamine D2 receptor blockade in vivo with the novel antipsychotics risperidone and remoxipride--an 123I-IBZM single photon emission tomography (SPET) study.
Topics: Adult; Antipsychotic Agents; Basal Ganglia; Benzamides; Cerebral Cortex; Dopamine D2 Receptor Antagonists; Female; Humans; Image Processing, Computer-Assisted; Iodine Radioisotopes; Isoxazoles; Male; Middle Aged; Neostriatum; Piperidines; Psychiatric Status Rating Scales; Psychotic Disorders; Pyrrolidines; Remoxipride; Risperidone; Schizophrenia; Tomography, Emission-Computed, Single-Photon | 1995 |
Dopamine D2 receptor occupancy by olanzapine or risperidone in young patients with schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzamides; Benzodiazepines; Brain; Brain Mapping; Contrast Media; Female; Humans; Iodine Radioisotopes; Male; Olanzapine; Pirenzepine; Psychiatric Status Rating Scales; Pyrrolidines; Receptors, Dopamine D2; Risperidone; Schizophrenia; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 1999 |
Striatal dopamine D2 receptor binding of risperidone in schizophrenic patients as assessed by 123I-iodobenzamide SPECT: a comparative study with olanzapine.
Topics: Adult; Aged; Antipsychotic Agents; Benzamides; Benzodiazepines; Contrast Media; Corpus Striatum; Dopamine D2 Receptor Antagonists; Female; Humans; Iodine Radioisotopes; Male; Middle Aged; Olanzapine; Pirenzepine; Psychotic Disorders; Pyrrolidines; Receptors, Dopamine D2; Risperidone; Schizophrenia; Tomography, Emission-Computed, Single-Photon | 2002 |
Occupancy of dopamine D2 receptors by the atypical antipsychotic drugs risperidone and olanzapine: theoretical implications.
Topics: Adult; Algorithms; Antipsychotic Agents; Benzamides; Benzodiazepines; Dopamine; Female; Humans; Male; Olanzapine; Psychiatric Status Rating Scales; Pyrrolidines; Radiopharmaceuticals; Receptors, Dopamine D2; Risperidone; Schizophrenia; Tomography, Emission-Computed, Single-Photon | 2004 |
12 other study(ies) available for 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide and risperidone
| Article | Year |
|---|---|
Dopamine D2 receptor occupancy in vivo and response to the new antipsychotic risperidone.
Topics: Adult; Antipsychotic Agents; Benzamides; Brain; Brain Mapping; Contrast Media; Dopamine D2 Receptor Antagonists; Humans; Iodine Radioisotopes; Isoxazoles; Male; Piperidines; Psychiatric Status Rating Scales; Pyrrolidines; Receptors, Dopamine D2; Risperidone; Schizophrenia; Schizophrenic Psychology; Tomography, Emission-Computed, Single-Photon | 1993 |
Striatal dopamine-2 receptor occupancy in psychotic patients treated with risperidone.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Benzamides; Brain Mapping; Dopamine Antagonists; Dose-Response Relationship, Drug; Female; Haloperidol; Humans; Male; Middle Aged; Obsessive-Compulsive Disorder; Psychiatric Status Rating Scales; Psychotic Disorders; Pyrrolidines; Receptors, Dopamine D2; Risperidone; Schizophrenia; Schizophrenic Psychology; Tomography, Emission-Computed, Single-Photon | 1996 |
D2 dopamine receptor occupancy: a crossover comparison of risperidone with clozapine therapy in schizophrenic patients.
Topics: Adult; Benzamides; Clozapine; Humans; Iodine Radioisotopes; Male; Middle Aged; Psychiatric Status Rating Scales; Pyrrolidines; Receptors, Dopamine D2; Risperidone; Schizophrenia | 1997 |
Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; Brain; Brain Mapping; Dopamine Antagonists; Drug Therapy, Combination; Female; Haloperidol; Humans; Male; Middle Aged; Neurologic Examination; Parkinson Disease, Secondary; Pyrrolidines; Receptors, Dopamine D2; Risperidone; Tomography, Emission-Computed, Single-Photon | 1997 |
Sertindole and dopamine D2 receptor occupancy in comparison to risperidone, clozapine and haloperidol - a 123I-IBZM SPECT study.
Topics: Adult; Antipsychotic Agents; Benzamides; Clozapine; Female; Haloperidol; Humans; Imidazoles; Indoles; Iodine Radioisotopes; Male; Middle Aged; Neostriatum; Pyrrolidines; Receptors, Dopamine D2; Risperidone; Schizophrenia; Tomography, Emission-Computed, Single-Photon | 1998 |
Psychomotor slowing, negative symptoms and dopamine receptor availability--an IBZM SPECT study in neuroleptic-treated and drug-free schizophrenic patients.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzamides; Brain; Dopamine Antagonists; Haloperidol; Humans; Middle Aged; Psychomotor Disorders; Pyrrolidines; Reaction Time; Receptors, Dopamine; Risperidone; Schizophrenia; Tomography, Emission-Computed, Single-Photon | 1998 |
Iodine-123-iodobenzamide SPECT assessment of dopamine D2 receptor occupancy in riperidone-treated schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; Brain; Clozapine; Contrast Media; Dose-Response Relationship, Drug; Female; Haloperidol; Humans; Iodine Radioisotopes; Male; Middle Aged; Pyrrolidines; Receptors, Dopamine D2; Risperidone; Schizophrenia; Tomography, Emission-Computed, Single-Photon | 1998 |
In vivo effects of olanzapine on striatal dopamine D(2)/D(3) receptor binding in schizophrenic patients: an iodine-123 iodobenzamide single-photon emission tomography study.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; Benzodiazepines; Case-Control Studies; Corpus Striatum; Dopamine Antagonists; Female; Humans; Iodine Radioisotopes; Male; Olanzapine; Pirenzepine; Psychotic Disorders; Pyrrolidines; Receptors, Dopamine; Risperidone; Schizophrenia; Tomography, Emission-Computed, Single-Photon | 1999 |
Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; Benzodiazepines; Corpus Striatum; Female; Health Status; Humans; Iodine Radioisotopes; Male; Olanzapine; Pirenzepine; Psychiatric Status Rating Scales; Pyrrolidines; Receptors, Dopamine D2; Risperidone; Schizophrenia; Schizophrenic Psychology; Tomography, Emission-Computed, Single-Photon | 2000 |
[Diminution of hand writing area and D2-dopamine receptor blockade. Results from treatment with typical and atypical neuroleptics].
Topics: Adult; Aged; Antipsychotic Agents; Benzamides; Clozapine; Dopamine Antagonists; Female; Haloperidol; Handwriting; Humans; Male; Middle Aged; Neostriatum; Pyrrolidines; Receptors, Dopamine; Risperidone; Schizophrenia, Paranoid; Therapeutic Equivalency; Tomography, Emission-Computed, Single-Photon | 2000 |
Dopamine D(2) receptor blockade in schizophrenia.
Topics: Antipsychotic Agents; Benzamides; Brief Psychiatric Rating Scale; Depression; Dopamine D2 Receptor Antagonists; Humans; Iodine Radioisotopes; Pyrrolidines; Receptors, Dopamine D2; Risperidone; Schizophrenia; Tomography, Emission-Computed, Single-Photon | 2001 |
Dopamine D2 receptor occupancy by risperidone: implications for the timing and magnitude of clinical response.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzamides; Brief Psychiatric Rating Scale; Corpus Striatum; Dominance, Cerebral; Female; Frontal Lobe; Humans; Male; Middle Aged; Occipital Lobe; Psychotic Disorders; Pyrrolidines; Receptors, Dopamine D2; Risperidone; Schizophrenia; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 2006 |